SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology ...

Prague headquartered clinical-stage firm SOTIO Biotech, which is owned by the Czech Republic's PPF Group, today announced it ...

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today presented the first preclinical data on SOT109, a novel antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17).

PRAGUE & AMSTERDAM--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its license and option ...

SOT109 leverages exatecan-based payload to produce potential best-in-class ADC for validated CDH17 target SOT109 expected to enter a first-in-human Phase 1 clinical trial in 2026 SOTIO Biotech ...

SOT109 leverages exatecan-based payload to produce potential best-in-class ADC for validated CDH17 target SOT109 expected to enter a first-in-human Phase 1 clinical trial in 2026 SOTIO ...

Three-program alliance with Synaffix reflects SOTIO's commitment to further broaden and advance innovative ADC pipeline SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF ...